Global Amyloidosis Therapeutics Market By Product Type (AG-10, ALN-ANG) And By End-Users/Application (AL Amyloidosis, AA Amyloidoses) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

  • AMR-985396
  • April 2021
  • Pharmaceuticals
  • 119 Pages
Download Sample

Report Preview

The Amyloidosis Therapeutics market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Amyloidosis Therapeutics market research report recommends a business strategy for present market participants to strengthen their position in the market.

According to the report, the Amyloidosis Therapeutics market size was USD xx million and it is expected to reach USD xx million by the end of 2028, with a CAGR of xx% during 2020-2028. While considering the volume shipments the global Amyloidosis Therapeutics market stood at xx (Units/Tons) in 2020 and expected to cross near about xx (units/Tons) by the end of forecast period.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Amyloidosis Therapeutics market along with their effects over the forecast period. Similarly, according to the region Amyloidosis Therapeutics market research report includes the study of opportunities available in the market situation.

The Amyloidosis Therapeutics market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2019
Forecast Period Covered 2019 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Product Type AG-10, ALN-ANG, ALN-TTRsc02, CAEL-101, Canakinumab, Others
Applications AL Amyloidosis, AA Amyloidoses, ATTR Amyloidoses, Others
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered Pfizer Inc., ProteoTech, Inc., Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics, Inc, Bellus Health Inc., Bsim2, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., GlaxoSmithKline Plc, Isis Pharmaceuticals, Inc., Prothena Corporation Plc, SOM Innovation Biotech SL

Global Amyloidosis Therapeutics Market Segmentation by Regions:
In regional analysis, Amyloidosis Therapeutics market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Amyloidosis Therapeutics market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Amyloidosis Therapeutics Market: Value and Forecast
  • U.S.
  • Canada
 
Europe Region for Amyloidosis Therapeutics Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 
Asia Pacific Region for Amyloidosis Therapeutics Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 
Latin America Region for Amyloidosis Therapeutics Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 
Middle East and Africa for Amyloidosis Therapeutics Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa



Global Amyloidosis Therapeutics Market Segmentation by Type:
On the basis of product type, global Amyloidosis Therapeutics market research report provides the production, revenue, price, and market share and growth rate of each type, primarily split into: AG-10, ALN-ANG, ALN-TTRsc02, CAEL-101, Canakinumab, Others

Global Amyloidosis Therapeutics Market Segmentation by Applications:
On the basis of the end users/applications, Amyloidosis Therapeutics research report analyze the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including: AL Amyloidosis, AA Amyloidoses, ATTR Amyloidoses, Others

Major Key Players for Global Amyloidosis Therapeutics Market:
The Amyloidosis Therapeutics market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Pfizer Inc., ProteoTech, Inc., Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics, Inc, Bellus Health Inc., Bsim2, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., GlaxoSmithKline Plc, Isis Pharmaceuticals, Inc., Prothena Corporation Plc, SOM Innovation Biotech SL

Important Points Covered by Report:
  • To analyze the value of the Amyloidosis Therapeutics market, according to the key region.
  • To study the Amyloidosis Therapeutics market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Amyloidosis Therapeutics market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Amyloidosis Therapeutics research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Amyloidosis Therapeutics market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Amyloidosis Therapeutics market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Amyloidosis Therapeutics market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Amyloidosis Therapeutics market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Amyloidosis Therapeutics market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Pfizer Inc.
  • ProteoTech, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics, Inc
  • Bellus Health Inc.
  • Bsim2
  • Celgene Corporation
  • Millennium Pharmaceuticals, Inc.
  • Onyx Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Isis Pharmaceuticals, Inc.
  • Prothena Corporation Plc
  • SOM Innovation Biotech SL
  • AG-10
  • ALN-ANG
  • ALN-TTRsc02
  • CAEL-101
  • Canakinumab
  • Others
  • AL Amyloidosis
  • AA Amyloidoses
  • ATTR Amyloidoses
  • Others

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Amyloidosis Therapeutics Market Snapshot
          2.1.1. Global Amyloidosis Therapeutics Market By Type,2019
               2.1.1.1.AG-10
               2.1.1.2.ALN-ANG
               2.1.1.3.ALN-TTRsc02
               2.1.1.4.CAEL-101
               2.1.1.5.Canakinumab
               2.1.1.6.Others
          2.1.2. Global Amyloidosis Therapeutics Market By Application,2019
               2.1.2.1.AL Amyloidosis
               2.1.2.2.AA Amyloidoses
               2.1.2.3.ATTR Amyloidoses
               2.1.2.4.Others
          2.1.3. Global Amyloidosis Therapeutics Market By End-use,2019
          2.1.4. Global Amyloidosis Therapeutics Market By Geography,2019

3. Global Amyloidosis Therapeutics Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Amyloidosis Therapeutics Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Amyloidosis Therapeutics Market Size (US$), By Type, 2018 – 2028

5. Global Amyloidosis Therapeutics Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Amyloidosis Therapeutics Market Size (US$), By Application, 2018 – 2028

6. Global Amyloidosis Therapeutics Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Amyloidosis Therapeutics Market Size (US$), By End-use, 2018 – 2028

7. Global Amyloidosis Therapeutics Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Amyloidosis Therapeutics Market Analysis, 2018 – 2028 
          7.2.1. North America Amyloidosis Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Amyloidosis Therapeutics Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Amyloidosis Therapeutics Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Amyloidosis Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Amyloidosis Therapeutics Market Analysis, 2018 – 2028 
          7.3.1.  Europe Amyloidosis Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Amyloidosis Therapeutics Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Amyloidosis Therapeutics Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Amyloidosis Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Amyloidosis Therapeutics Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Amyloidosis Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Amyloidosis Therapeutics Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Amyloidosis Therapeutics Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Amyloidosis Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Amyloidosis Therapeutics Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Amyloidosis Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Amyloidosis Therapeutics Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Amyloidosis Therapeutics Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Amyloidosis Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Amyloidosis Therapeutics Market Analysis, 2018 – 2028 
          7.6.1.  MEA Amyloidosis Therapeutics Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Amyloidosis Therapeutics Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Amyloidosis Therapeutics Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Amyloidosis Therapeutics Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Amyloidosis Therapeutics Providers
        8.4.1 Pfizer Inc.
                8.1.1 Business Description
                8.1.2 Pfizer Inc. Geographic Operations
                8.1.3 Pfizer Inc. Financial Information
                8.1.4 Pfizer Inc. Product Positions/Portfolio
                8.1.5 Pfizer Inc. Key Developments
        8.4.2 ProteoTech, Inc.
                8.2.1 Business Description
                8.2.2 ProteoTech, Inc. Geographic Operations
                8.2.3 ProteoTech, Inc. Financial Information
                8.2.4 ProteoTech, Inc. Product Positions/Portfolio
                8.2.5 ProteoTech, Inc. Key Developments
        8.4.3 Alnylam Pharmaceuticals, Inc.
                8.3.1 Business Description
                8.3.2 Alnylam Pharmaceuticals, Inc. Geographic Operations
                8.3.3 Alnylam Pharmaceuticals, Inc. Financial Information
                8.3.4 Alnylam Pharmaceuticals, Inc. Product Positions/Portfolio
                8.3.5 Alnylam Pharmaceuticals, Inc. Key Developments
        8.4.4 Arcturus Therapeutics, Inc
                8.4.1 Business Description
                8.4.2 Arcturus Therapeutics, Inc Geographic Operations
                8.4.3 Arcturus Therapeutics, Inc Financial Information
                8.4.4 Arcturus Therapeutics, Inc Product Positions/Portfolio
                8.4.5 Arcturus Therapeutics, Inc Key Developments
        8.4.5 Bellus Health Inc.
                8.5.1 Business Description
                8.5.2 Bellus Health Inc. Geographic Operations
                8.5.3 Bellus Health Inc. Financial Information
                8.5.4 Bellus Health Inc. Product Positions/Portfolio
                8.5.5 Bellus Health Inc. Key Developments
        8.4.6 Bsim2
                8.6.1 Business Description
                8.6.2 Bsim2 Geographic Operations
                8.6.3 Bsim2 Financial Information
                8.6.4 Bsim2 Product Positions/Portfolio
                8.6.5 Bsim2 Key Developments
        8.4.7 Celgene Corporation
                8.7.1 Business Description
                8.7.2 Celgene Corporation Geographic Operations
                8.7.3 Celgene Corporation Financial Information
                8.7.4 Celgene Corporation Product Positions/Portfolio
                8.7.5 Celgene Corporation Key Developments
        8.4.8 Millennium Pharmaceuticals, Inc.
                8.8.1 Business Description
                8.8.2 Millennium Pharmaceuticals, Inc. Geographic Operations
                8.8.3 Millennium Pharmaceuticals, Inc. Financial Information
                8.8.4 Millennium Pharmaceuticals, Inc. Product Positions/Portfolio
                8.8.5 Millennium Pharmaceuticals, Inc. Key Developments
        8.4.9 Onyx Pharmaceuticals, Inc.
                8.9.1 Business Description
                8.9.2 Onyx Pharmaceuticals, Inc. Geographic Operations
                8.9.3 Onyx Pharmaceuticals, Inc. Financial Information
                8.9.4 Onyx Pharmaceuticals, Inc. Product Positions/Portfolio
                8.9.5 Onyx Pharmaceuticals, Inc. Key Developments
        8.4.10 GlaxoSmithKline Plc
                8.10.1 Business Description
                8.10.2 GlaxoSmithKline Plc Geographic Operations
                8.10.3 GlaxoSmithKline Plc Financial Information
                8.10.4 GlaxoSmithKline Plc Product Positions/Portfolio
                8.10.5 GlaxoSmithKline Plc Key Developments
        8.4.11 Isis Pharmaceuticals, Inc.
                8.11.1 Business Description
                8.11.2 Isis Pharmaceuticals, Inc. Geographic Operations
                8.11.3 Isis Pharmaceuticals, Inc. Financial Information
                8.11.4 Isis Pharmaceuticals, Inc. Product Positions/Portfolio
                8.11.5 Isis Pharmaceuticals, Inc. Key Developments
        8.4.12 Prothena Corporation Plc
                8.12.1 Business Description
                8.12.2 Prothena Corporation Plc Geographic Operations
                8.12.3 Prothena Corporation Plc Financial Information
                8.12.4 Prothena Corporation Plc Product Positions/Portfolio
                8.12.5 Prothena Corporation Plc Key Developments
        8.4.13 SOM Innovation Biotech SL
                8.13.1 Business Description
                8.13.2 SOM Innovation Biotech SL Geographic Operations
                8.13.3 SOM Innovation Biotech SL Financial Information
                8.13.4 SOM Innovation Biotech SL Product Positions/Portfolio
                8.13.5 SOM Innovation Biotech SL Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Amyloidosis Therapeutics Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Amyloidosis Therapeutics Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Amyloidosis Therapeutics Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Amyloidosis Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Amyloidosis Therapeutics Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Amyloidosis Therapeutics Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Amyloidosis Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Amyloidosis Therapeutics Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Amyloidosis Therapeutics Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Amyloidosis Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Amyloidosis Therapeutics Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Amyloidosis Therapeutics Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Amyloidosis Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Amyloidosis Therapeutics Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Amyloidosis Therapeutics Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Amyloidosis Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Amyloidosis Therapeutics: Market Segmentation 
FIG. 2 Global Amyloidosis Therapeutics Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Amyloidosis Therapeutics Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Amyloidosis Therapeutics Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Amyloidosis Therapeutics Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Amyloidosis Therapeutics Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Amyloidosis Therapeutics Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Amyloidosis Therapeutics Providers, 2019
FIG. 11 Global Amyloidosis Therapeutics Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Amyloidosis Therapeutics Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Amyloidosis Therapeutics Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Amyloidosis Therapeutics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Amyloidosis Therapeutics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Amyloidosis Therapeutics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Amyloidosis Therapeutics Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Amyloidosis Therapeutics Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Amyloidosis Therapeutics market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Amyloidosis Therapeutics Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Amyloidosis Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  North America Amyloidosis Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  North America Amyloidosis Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Europe Amyloidosis Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  Europe Amyloidosis Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  Europe Amyloidosis Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Amyloidosis Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Amyloidosis Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Amyloidosis Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Latin America Amyloidosis Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Amyloidosis Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Amyloidosis Therapeutics Market Value, By Country, 2018 – 2028
TABLE  MEA Amyloidosis Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  MEA Amyloidosis Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  MEA Amyloidosis Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ProteoTech, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Alnylam Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Arcturus Therapeutics, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bellus Health Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bsim2: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Celgene Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Millennium Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Onyx Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline Plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Isis Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Prothena Corporation Plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  SOM Innovation Biotech SL: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Amyloidosis Therapeutics Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Amyloidosis Therapeutics Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Amyloidosis Therapeutics Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Amyloidosis Therapeutics Market, By Geography, 2019 (US$ Mn)
FIG.  Global Amyloidosis Therapeutics Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Amyloidosis Therapeutics Providers, 2016
FIG.  Global Amyloidosis Therapeutics Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global AG-10 Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global ALN-ANG Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global ALN-TTRsc02 Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global CAEL-101 Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Canakinumab Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Amyloidosis Therapeutics Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global AL Amyloidosis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global AA Amyloidoses Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global ATTR Amyloidoses Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Amyloidosis Therapeutics Market Value, 2018 – 2028, (US$ Mn)